Influence of Oxytocin on Resting State Neurophysiological Measures
NCT ID: NCT03255148
Last Updated: 2019-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
56 participants
INTERVENTIONAL
2017-07-24
2018-05-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Influence of Oxytocin on Socio-communicative Sensitivity
NCT03096249
Influence of Oxytocin on Approach-avoidance Tendencies to Social and Non-social Stimuli
NCT04443647
Effects of Oxytocin on Emotion Recognition and Response Inhibition
NCT02350946
The Influence of Oxytocin on Automatic Imitation Behaviour in Healthy Adults
NCT01767025
Oxytocin Effects on Self and Other Processing
NCT02963194
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Please note that this study is part of a larger study in which the investigators also asses the influence of oxytocin on neurophysiological responses elicited by direct gaze
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oxytocin
Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
Oxytocin
Syntocinon nasal spray
Placebo
saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
Placebo
Placebo nasal spray
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxytocin
Syntocinon nasal spray
Placebo
Placebo nasal spray
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* male
* age between 18 and 35
* Normal or adjusted-to-normal vision (with lenses only)
* Dutch as mother tongue
Exclusion Criteria
* female
* age below 18 or above 35
* Need to wear glasses
* Dutch not as mother tongue
18 Years
38 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Research Foundation Flanders
OTHER
KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kaat Alaerts
Prof. Dr. Kaat Alaerts
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kaat Alaerts, PhD
Role: PRINCIPAL_INVESTIGATOR
KU Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KU Leuven
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SingleOT_REST_S56327
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.